Skip to main content
SpringerLink
Log in

Lamivudine/rituximab

Lack of efficacy of lamivudine in preventing rituximab-associated hepatitis B virus reactivation (leading to hepatitis in one patient): 2 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; R-FFP: rituximab, fresh frozen plasma; R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; R-FC: rituximab, fludarabine, cyclophosphamide

Reference

  • Wang YH, et al. Efficacy of prophylactic lamivudine to prevent hepatitis B virus reactivation in B-cell lymphoma treated with rituximab-containing chemotherapy. Supportive Care in Cancer 21: 1265-71, No. 5, 1 May 2013 - China

    Article  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lamivudine/rituximab. Reactions Weekly 1541, 173 (2015). https://doi.org/10.1007/s40278-015-8325-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-015-8325-x

Search

Navigation